Michele E.
- Country
- Italy
- Department
- N/A
Research Overview
- Evaluation of Colchicine Efficacy in Reducing NT-proBNP Levels in Patients with Acute Decompensated Heart Failure: A Randomized, Double-Blind, Placebo-Controlled Trial
- A Phase 3, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Oral Levosimendan in Patients with Pulmonary Hypertension and HFpEF
- Phase IIb Randomized Double‑Blind Placebo‑Controlled Study of Eplontersen Plus ALXN2220 Versus Eplontersen + Placebo in Adults with Transthyretin‑Mediated Amyloid Cardiomyopathy
Data & Insights
Has run more than one trial at 237 of 788 partner sites.
Specializations
Transthyretin amyloidosis and amyloid cardiomyopathy
Clinical research activity is strongly centered on transthyretin amyloid cardiomyopathy, including symptomatic, newly diagnosed, hereditary, wild-type, and asymptomatic carrier populations. The therapeutic focus includes disease modification, long-term management, and prevention of cardiac involvement in ATTR-CM and related cardiac amyloidosis.
- ATTR-CM
- Transthyretin amyloidosis
- Cardiac amyloidosis
- Asymptomatic TTR variant carriers
Interest also extends to imaging-based detection and non-invasive characterization of amyloid deposition, alongside therapies aimed at stabilizing or reducing transthyretin-driven cardiac disease.
Heart failure, myocarditis, and inflammatory cardiac disease
The investigator is involved in studies across the spectrum of heart failure, with attention to HFpEF, HFmrEF, and acute decompensation, as well as inflammatory myocardial disorders such as acute myocarditis and severe cardiac inflammation. Therapeutic interests include symptom control, functional improvement, and stabilization of cardiac status.
- Heart failure with preserved ejection fraction
- Acute decompensated heart failure
- Acute myocarditis
- Cardiac inflammation
Research also includes cardiomyopathy phenotypes linked to structural and inflammatory myocardial disease, with a focus on improving exercise tolerance and clinical outcomes.
Hypertrophic cardiomyopathy and structural heart disease
Another major area of interest is hypertrophic cardiomyopathy, including obstructive and non-obstructive forms, with studies addressing symptoms, exercise limitation, and myocardial remodeling. The clinical landscape also includes related genetic cardiomyopathies such as BAG3-associated dilated cardiomyopathy.
- Symptomatic hypertrophic cardiomyopathy
- Non-obstructive hypertrophic cardiomyopathy
- Obstructive hypertrophic cardiomyopathy
- BAG3-associated dilated cardiomyopathy
This area reflects sustained involvement in therapies targeting myocardial contractility, cardiac structure, and patient-reported health status in inherited and structural heart disease.
Atherosclerotic cardiovascular disease and lipid-related prevention
Clinical trial activity includes prevention and risk reduction in atherosclerotic cardiovascular disease, coronary artery disease, and high-risk primary prevention populations. The therapeutic focus spans lipid-lowering strategies and emerging approaches for lipoprotein(a)-driven cardiovascular risk.
- Atherosclerotic cardiovascular disease
- Coronary artery disease
- Elevated lipoprotein(a)
- High cardiovascular risk
Research also includes prevention in patients with diabetes and established cardiovascular risk profiles, with attention to reducing major adverse cardiovascular events.
Atrial fibrillation, pulmonary hypertension, and advanced cardiovascular care
The investigator’s portfolio also covers atrial fibrillation with stroke prevention and left atrial appendage closure, as well as pulmonary arterial hypertension and pulmonary hypertension linked to left heart disease. Additional work includes advanced cardiovascular diagnostics and management of complex cardiac conditions.
- Atrial fibrillation
- Left atrial appendage closure
- Pulmonary arterial hypertension
- Pulmonary hypertension with HFpEF
These areas reflect engagement in anticoagulation alternatives, hemodynamic disease management, and cardiology innovation across high-risk cardiovascular populations.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.